Immunometabolic remodelling of monocyte and macrophage responses by metformin in non-diabetic CVD
Inflammation is an important way of our bodies protecting us from infection and ill health. But, when inflammation is sustained and badly controlled, it can damage the cells in our heart and blood vessels and be responsible for the development of heart diseases. Existing anti-inflammatory medicines have been tested as a possible treatment for heart diseases, to no avail. In this project, Dr Graham Rena and his team will test whether a common anti-diabetic drug could be used to tackle damaging inflammation. Metformin is a drug prescribed to many people with diabetes to help control their blood sugar levels. It’s also thought to reduce heart and circulation problems in these people through another mechanism. In fact, these researchers have shown that metformin has also anti-inflammatory effects. The team will study metformin’s anti-inflammatory effects in more details to understand how it regulates the activity of immune cells called monocyte and macrophages. The work could lead to metformin – a safe drug that’s already on the market - becoming a new treatment for people living with heart diseases.
Project details
| Grant amount | £218,202 |
|---|---|
| Grant type | Project Grants |
| Application type | Project Grant |
| Start Date | 01 September 2019 |
| Duration | 3 years |
| Reference | PG/18/79/34106 |
| Status | In Progress |
